WednesdayJun 24, 2020 11:46 am

Vivos Therapeutics, Inc. Launches Promising Treatment of Mild to Moderate Obstructive Sleep Apnea in Adults

Obstructive Sleep Apnea (“OSA”) impacts up to 1 billion people globally, including 54 million Americans Estimates suggest OSA costs the U.S. economy $165 billion annually Vivos System offers significant advantages over traditional OSA treatment approaches Over 4,300 healthcare professionals registered for Vivos’ education and training Summit in March 2020, with strong and growing interest in this disruptive new technology Vivos Therapeutics’ Vivos System is the first treatment modality for mild to moderate OSA based on the ability to remodel and enhance the function, size, and shape of the human airway, in most cases avoiding the need for lifelong interventions. The…

Continue Reading

WednesdayJun 17, 2020 12:49 pm

Vivos Therapeutics, Inc.’s Technology Offers Fresh Hope to Sleep Apnea Sufferers

Obstructive Sleep Apnea (“OSA”) is a pervasive disorder impacting the lives of up to 1 billion people globally and approximately 54 million Americans. OSA has been linked to increased rates of cancer, hypertension, cardiovascular disease, ADHD, Alzheimer’s, diabetes, dementia, and ultimately—up to 10-year shorter lifespans. Current front-line treatment options such as CPAP are intrusive and must be used every night for life in order to be effective. Surgical options and implants can be risky and expensive. The Vivos System is the first treatment modality for mild to moderate OSA which has demonstrated the ability to remodel and enhance the size,…

Continue Reading

FridayJun 05, 2020 11:07 am

Vivos Therapeutics Inc. is “One to Watch”

Obstructive sleep apnea affects millions of people of all ages. It is estimated that OSA costs the US economy $165B annually. The Vivos technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated hundreds of millions of people globally who suffer from OSA. As dentists have hundreds of patients of all ages suffering from OSA, the Vivos System presents a multi-million dollar revenue opportunity for dental practices. Vivos is helping address challenges throughout the world, reducing the overall cost of health care by focusing on a prevalent condition which is linked to many of the most expensive health…

Continue Reading

ThursdayJun 04, 2020 11:45 am

Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview

POAI boasts unique historical database documenting actual drug responses of tumors – the largest in the world with over 150,000 tumors across 137 types Drug discovery funding for subsidiary Helomics planned through relationships with large pharmaceutical companies Company planning to acquire two new biological firms in the precision medicine space Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven medicine company focused on applying data and artificial intelligence (AI) to cancer personalized medicine and drug discovery. In a recent interview (http://nnw.fm/o7Ysq), POAI director and CEO Dr. Carl Schwartz discussed the acquisition of two biological firms, along with details about the company’s…

Continue Reading

TuesdayJun 02, 2020 12:34 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

POAI addresses pressing need for a multi-omic approach in field of precision medicine Global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 Predictive Oncology’s ‘claim to fame’ is its inventory of over 150,000 tumors covering over 137 types of cancer, with over 30,000 related to ovarian cancer In the burgeoning world of precision medicine, Predictive Oncology Inc. (NASDAQ: POAI) appears ideally positioned to address one of the most pressing problems in the industry: the need for a multi-omic approach to precision therapy that may offer markedly improved patient outcomes over just genomics alone.…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050